New and updated clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Innovent, Primmune.
New and updated preclinical data presented at the American Association for Cancer Research annual meeting in Orlando, Fla., by: Fusion Pharmaceuticals, Ose Immunotherapeutics, Salarius Pharmaceuticals.
PHI-501 is a novel pan-RAF inhibitor being developed for acute myeloid leukemia. Big data, an artificial intelligence (AI)-based drug discovery platform and cell-based investigation identified PHI-501 as potentially useful against melanoma, and researchers from Pharos Ibio Co. Ltd. presented preclinical evaluation of the drug for this new indication.
Cyclin-dependent kinases (CDK) are serine/threonine kinases that act as regulatory enzymes involved in cell proliferation. The dysregulation of CDK activity occurs through overexpression of cyclin E1, a binding partner of CDK2, which is observed in several cancers such as high-grade serous ovarian cancer (HGSOC), bladder cancer, gastric cancer and estrogen receptor-positive breast cancer, among others. Selective inhibition of CDK2 may thus be considered a therapeutic approach to regaining cell cycle control.
New and updated clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Beigene, Cellular Invlos, Karyopharm, Kinnate, Mapkure, Mendus, Mink, Nouscom, Relay, Repare, Scancell, Sonnet, Springworks, Transgene, Triumvira.
Alterations in hepatocyte growth factor receptor (c-Met) can be oncogenic in non-small-cell lung cancer (NSCLC) as well as other cancer types. Antibody-drug conjugates (ADCs) that target c-Met have been developed to treat c-Met-expressing tumors.
RSS
